Abakkus Venture Opportunities Fund anchors Credent Connect N Care's IPO

When a fund run by one of India's most-tracked equity investors puts money into a company's IPO before it even lists, retail investors take notice. That's what happened with Credent Connect N Care Ltd, a Delhi-based healthcare logistics and workforce-solutions provider, whose SME IPO anchor book in August 2026 included Sunil Singhania's Abakkus Venture Opportunities Fund — and Abakkus wasn't the only tracked name already in the stock before it listed.

CMP ₹358 · Market cap ₹652 crore (screener.in, consolidated basis, Sept 18, 2026 close — check the live price before acting) · P/E 35.3x — against Entero Healthcare Solutions, its closest (imperfect) listed reference point, at roughly 58x (also consolidated). Credent's own P/E has already re-rated sharply from 18.7x at its IPO price. Since listing in August 2026, the stock has traded in a ₹309–₹380 range — the ₹357-358 level has held up, not moved much, over the past two weeks.

What Credent Connect N Care actually does

Incorporated in 2015, Credent Connect N Care is the outsourced backend for India's healthcare ecosystem. Picture a routine blood test: a phlebotomist visits the patient and draws the sample, hands it to a runner, who collects samples from multiple patients and delivers them to a diagnostic lab for testing — Credent (branded C3) runs that entire chain. On the other side, when a lab needs a reagent for its testing machines, Credent coordinates with the reagent maker to get it delivered, often inter-city by air, road or rail. It also runs C3 Wellness (corporate vaccination drives, health camps, on-site staffing) and C3 Post (courier aggregation, cash-on-delivery reconciliation and cold-chain logistics for healthcare shipments).

Independently confirmed: the company works with 2,500+ partner labs, a 6,000+-strong field force, and serves roughly 280 domestic customers — including a confirmed partnership with Dr. Lal PathLabs. Per the company's own FY26 investor materials, contracts typically run 3 years on a revenue-share or per-collection basis.

FY26 revenue came in at ₹214 crore, against ₹76-78 crore in each of FY24 and FY25 — but that comparison isn't apples-to-apples: FY24/FY25 were reported standalone, while FY26 is consolidated, following three acquisitions completed during the year (Credent Healthcare Private Limited, now a wholly-owned subsidiary; Credent Team Private Limited; and Alltrak Technologies Private Limited, a logistics-tech platform, acquired for ₹10.84 crore). Net profit rose from ₹2.25 crore (FY25 standalone) to ₹18.45 crore (FY26 consolidated). Return ratios jumped even more sharply — ROE from 15.20% to 61.81%, and ROCE from 16.96% to 40.00% — though a large part of that jump reflects the newly-consolidated, higher-margin subsidiaries entering the base, not organic improvement in the pre-existing logistics business alone.

The segment mix shifted hard toward higher-margin services in FY26:

Segment FY25 (standalone) FY26 (consolidated) --------- Healthcare Services (phlebotomy, home collection) 12.18% of revenue 43.04% of revenue Logistics Services (transport, cold chain) 64.69% of revenue 25.26% of revenue Operations & Supply Chain Management 13.01% of revenue 24.93% of revenue EBITDA margin 6.41% 13.29% PAT margin 2.88% 8.61%

How much of that jump is genuinely organic, versus simply newly-consolidated revenue, isn't something the headline growth number tells you — it needs a like-for-like breakout the company hasn't disclosed to answer properly.

Smart money got in well before the IPO

Abakkus's anchor allocation wasn't its first stake here. Per the company's RHP shareholding pattern at the time of filing, Ashish Kacholia and Abakkus Venture Opportunities Fund each bought in on July 23, 2026, at ₹187/share — Kacholia around 2.02%, Abakkus Venture Opportunities Fund around 1.21% — just ₹2 below the eventual IPO price of ₹189. Separately, in the August anchor round, Abakkus Venture Opportunities Fund and Mint Focussed Growth Fund (a different manager, not part of Abakkus) each took 2.64 lakh more shares at ₹189. Their combined current post-listing holdings aren't independently confirmed here, but two of the market's most-tracked names were clearly in this stock before the public ever got to apply for it.

Profit on paper, cash still on the road FY26 net profit was ₹18.45 crore — but operating cash flow swung to negative ₹6.62 crore, a reversal from positive ₹5.48 crore in FY25. Trade receivables more than tripled, from ₹17.90 crore to ₹58.83 crore, implying debtor days of roughly 100 — a genuine working-capital stretch that the company's own FY26 earnings materials flag directly, not just an artifact of one source's read. The swing from positive to negative operating cash flow in the very year profit jumped is worth watching in the next year or two of results.

Customer concentration adds to that picture: the top 10 customers made up 81.76% of FY26 revenue (down from 83.31% in FY25 and 87.92% in FY24), and the single largest customer's share has moved around a fair bit year to year — 18.70% in FY24, 22.43% in FY25, and 15.76% in FY26. Concentration in the largest single customer has actually eased, but a business this dependent on a short list of large clients can still see growth swing hard if even one of them slows down or renegotiates terms.

One clean positive: this was a 100% fresh-issue IPO with no offer-for-sale component, so every rupee raised went into the company rather than to selling shareholders — the promoter Sharma family's stake diluted from 87.52% pre-IPO to 63.75% post-listing purely from the new shares issued, not from cashing out.

Management's own guidance: "Vision 2030"

Per the company's FY26 earnings materials, management has laid out a four-phase roadmap it calls Vision 2030, alongside an aspiration — not a formal target — of roughly 45% revenue CAGR through FY30:

- FY27 — Sector Sprint: focus sales and operations on six named sectors (Diagnostics, Vaccines, Pharma, Clinical Trials/CRO, Cord Blood, IVD companies). - FY28 — Platform Consolidation: integrate all service lines onto the Alltrak technology platform; a dedicated healthcare warehouse targeted to be fully operational. - FY29 — Sector Leadership: aim for category leadership across those six sectors. - FY30 — International Expansion: evaluate entry into South Asia, the Middle East and Africa, explicitly flagged by management as "subject to regulatory and commercial feasibility" — not a committed plan.

This is management's own stated ambition, not an independently verified forecast or a promise — treat the 45% CAGR figure and the FY30 international step accordingly.

How does its valuation compare with a listed peer?

By the company's own account, there's no clean listed peer for this specific mix of logistics, staffing and healthcare-services revenue. The closest available reference point is Entero Healthcare Solutions, India's largest listed pharmaceutical and healthcare-products distribution platform, which sits in a different part of the healthcare supply chain (product distribution, not logistics-and-staffing). Both companies' numbers below are read on the same, consolidated basis, straight off screener.in as of the Sept 18, 2026 close:

Credent Connect N Care Entero Healthcare Solutions --------- CMP ₹358 ₹1,732 Market cap ₹652 crore ₹7,540 crore Stock P/E (consolidated) 35.3x ~58.4x Since-listing / recent range ₹309–₹380 (since Aug 2026 listing) ₹944–₹1,920 (52-week)

Entero's price and market cap have actually eased a little since this article first ran (from roughly ₹1,810/share and ₹7,872 crore), while its P/E has widened to ~58x — a sign its trailing profit base has also narrowed, not a sign the stock has gotten cheaper. Credent's own consolidated P/E, at 35.3x, is barely changed from the 35x figure reported earlier this month.

A lower P/E than one much-bigger, differently-structured peer doesn't establish that Credent is "cheap" — and Credent's own multiple has already nearly doubled since listing (from 18.7x at issue price), which matters more to anyone buying today than the gap to Entero does. Management separately pegs India's diagnostic-logistics market at roughly 20% of the country's diagnostics-industry spend, itself projected to nearly double from USD 16.5 billion (FY25E) to USD 31.5 billion (FY30E) — a real sector tailwind, though it says nothing about whether Credent specifically keeps its share of it.

Should you chase it?

Two tracked smart-money names being in this stock before it even listed is a reason to research Credent Connect N Care, not a reason to buy it blindly — especially with the fuller picture on the table: a headline growth number that's partly a standalone-to-consolidated accounting shift following three FY26 acquisitions, operating cash flow that swung negative in the very year profit jumped, revenue concentrated in a handful of large customers, and a stock that has already roughly doubled from its issue price and nearly doubled its own earnings multiple since listing. Management's own Vision 2030 roadmap and 45% CAGR aspiration are worth knowing, but they're targets, not results. The no-OFS structure and the pre-IPO buy-in from two well-tracked investors are genuine positives, but they're not a substitute for reading the numbers yourself. Read the RHP and the FY26 financial statements before forming a view either way; this is a small, recently-listed, illiquid SME stock, not a blue chip.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- Credent Connect N Care — screener.in (standalone) - Credent Connect N Care — screener.in (consolidated) - Credent Connect N Care investor presentation (NSE filing) - Entero Healthcare Solutions — screener.in (standalone) - Entero Healthcare Solutions — screener.in (consolidated)